GlassScriptPhysician profile
Lena A Kramer
NPI 1942714183
$5,224.02
in general payments reported to CMS, 2019-2025
17 companies · $754 in 2025
The $754 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $918 · 2022: $1,150 · 2023: $905 · 2024: $1,497 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,077 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,076.51 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,028.96 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $958.52 | 2021-2025 | |
| Genzyme Corporation | $512.91 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $495.82 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $483.96 | 2021-2025 | Dupixent, Libtayo |
| Amgen INC. | $390.78 | 2022-2025 | Otezla, Otezla |
| Dermavant Sciences, INC. | $265.49 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $253.01 | 2021-2024 | |
| Leo Pharma INC. | $194.00 | 2022-2025 | Adbry |
| Pfizer INC. | $138.43 | 2021-2024 | |
| Incyte Corporation | $125.67 | 2021-2023 | Opzelura |
| Lilly USA, LLC | $82.00 | 2021-2022 | |
| Galderma Laboratories, L.P. | $72.76 | 2023-2025 | Aklief, Epsolay, Oracea |
| Arcutis Biotherapeutics, INC. | $68.91 | 2023-2025 | Zoryve |
| Organon LLC | $59.28 | 2025 | Vtama |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $48.12 | 2021-2025 | Bimzelx |
| Biofrontera INC. | $45.40 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lena Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.